Home » CytRx Licenses Non-RNAi Assets to SynthRx

CytRx Licenses Non-RNAi Assets to SynthRx

Oct 31, 2003
Premium

CytRx said last week that it has exclusively licensed its phase III sickle cell disease drug Flocor, as well as its OptiVax vaccine delivery technology, to SynthRx, a Houston-based startup firm founded and run by Robert Hunter, a CytRx co-founder and chairman of the University of Texas’ department of pathology and laboratory medicine.

The out-licensing of these assets, leftovers from before CytRx acquired Global Genomics and reorganized under president and CEO Steve Kriegsman, has been a goal of the company for some time.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Not Always an Answer

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

CRISPR Acceptance or Not?

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

This Week in Science

In Science this week: research regulation and reporting requirement reform, and more.

Building Up Numbers

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Aug
07
Featured Webinar

Rapid and Comprehensive NGS Variant Interpretation Using Web-Based Software

Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.

What's Popular?

In Gene Silencing/Gene Editing

  1. CRISPR Interference Platform Maps Genetic Interactions on Large Scale

  2. CRISPR Genome Editing May Cause More Complex Rearrangements, Deletions Than Previously Thought

  3. Inscripta Confirms CRISPR-MAD7 Editing Activity in Mammalian Cells, Releases New MAD2 Enzyme

    Premium

  4. Locus Biosciences Acquires EpiBiome Bacteriophage Discovery Platform

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.